Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease

DSpace/Manakin Repository

Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease

Citable link to this page

 

 
Title: Stage-Specific Action of Matrix Metalloproteinases Influences Progressive Hereditary Kidney Disease
Author: Zeisberg, Michael; Khurana, Mona; Rao, Velidi H.; Cosgrove, Dominic; Rougier, Jean-Philippe; Werner, Michelle C.; Shield III, Charles F.; Werb, Zena; Kalluri, Raghu

Note: Order does not necessarily reflect citation order of authors.

Citation: Zeisberg, Michael, Mona Khurana, Velidi H. Rao, Dominic Cosgrove, Jean-Philippe Rougier, Michelle C. Werner, Charles F. Shield, Zena Werb, and Raghu Kalluri. 2006. Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Medicine 3(4): e100.
Full Text & Related Files:
Abstract: Background: Glomerular basement membrane (GBM), a key component of the blood-filtration apparatus in the in the kidney, is formed through assembly of type IV collagen with laminins, nidogen, and sulfated proteoglycans. Mutations or deletions involving \(\alpha\)3(IV), \(\alpha\)4(IV), or \(\alpha\)5(IV) chains of type IV collagen in the GBM have been identified as the cause for Alport syndrome in humans, a progressive hereditary kidney disease associated with deafness. The pathological mechanisms by which such mutations lead to eventual kidney failure are not completely understood. Methods and Findings: We showed that increased susceptibility of defective human Alport GBM to proteolytic degradation is mediated by three different matrix metalloproteinases (MMPs)—MMP-2, MMP-3, and MMP-9—which influence the progression of renal dysfunction in \(\alpha 3(IV)^{−/−}\) mice, a model for human Alport syndrome. Genetic ablation of either MMP-2 or MMP-9, or both MMP-2 and MMP-9, led to compensatory up-regulation of other MMPs in the kidney glomerulus. Pharmacological ablation of enzymatic activity associated with multiple GBM-degrading MMPs, before the onset of proteinuria or GBM structural defects in the \(\alpha 3(IV)^{−/−}\) mice, led to significant attenuation in disease progression associated with delayed proteinuria and marked extension in survival. In contrast, inhibition of MMPs after induction of proteinuria led to acceleration of disease associated with extensive interstitial fibrosis and early death of \(\alpha\)3(IV)−/− mice. Conclusions: These results suggest that preserving GBM/extracellular matrix integrity before the onset of proteinuria leads to significant disease protection, but if this window of opportunity is lost, MMP-inhibition at the later stages of Alport disease leads to accelerated glomerular and interstitial fibrosis. Our findings identify a crucial dual role for MMPs in the progression of Alport disease in \(\alpha 3(IV)^{−/−}\) mice, with an early pathogenic function and a later protective action. Hence, we propose possible use of MMP-inhibitors as disease-preventive drugs for patients with Alport syndrome with identified genetic defects, before the onset of proteinuria.
Published Version: doi:10.1371/journal.pmed.0030100
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1391977/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:10212563
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters